SEC Info - Brooklyn ImmunoTherapeutics, Inc. - ‘S-4/A’ on 11/25/20

SEC Info℠

Home

My Interests

Help

Please Sign In

Brooklyn ImmunoTherapeutics, Inc. – ‘S-4/A’ on 11/25/20 – ‘EX-101.DEF’

On: Wednesday, 11/25/20, at 6:13am ET · Accession #: 1493152-20-22484 · File #: 333-249249

Previous ‘S-4’: ‘S-4’ on 10/2/20 · Next: ‘S-4/A’ on 12/22/20 · Latest: ‘S-4/A’ on 1/20/21 · 35 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/25/20  NTN Buzztime Inc.                 S-4/A                207:22M                                    M2 Compliance LLC/FA

Pre-Effective Amendment to Registration Statement – Securities for a Merger — Form S-4 — SA’33
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration Statement   HTML   4.43M 
                - Securities for a Merger                                        
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     58K 
 3: EX-10.16(A)  Material Contract                                  HTML     72K 
 4: EX-10.16(B)  Material Contract                                  HTML     74K 
 5: EX-10.17(A)  Material Contract                                  HTML     72K 
 6: EX-10.17(B)  Material Contract                                  HTML     58K 
 7: EX-10.17(C)  Material Contract                                  HTML     74K 
 8: EX-10.17(D)  Material Contract                                  HTML     66K 
 9: EX-10.18    Material Contract                                   HTML     74K 
10: EX-10.19(A)  Material Contract                                  HTML    235K 
11: EX-10.19(B)  Material Contract                                  HTML     61K 
12: EX-10.19(C)  Material Contract                                  HTML     72K 
13: EX-10.20    Material Contract                                   HTML    126K 
14: EX-10.21    Material Contract                                   HTML     68K 
15: EX-10.22    Material Contract                                   HTML     71K 
16: EX-10.23(A)  Material Contract                                  HTML    284K 
17: EX-10.23(B)  Material Contract                                  HTML     63K 
18: EX-10.23(C)  Material Contract                                  HTML     66K 
19: EX-10.23(D)  Material Contract                                  HTML    101K 
20: EX-10.24(A)  Material Contract                                  HTML    219K 
21: EX-10.24(B)  Material Contract                                  HTML     77K 
22: EX-10.24(C)  Material Contract                                  HTML     66K 
23: EX-23.4     Consent of Expert or Counsel                        HTML     54K 
24: EX-23.5     Consent of Expert or Counsel                        HTML     54K 
25: EX-99.1     Miscellaneous Exhibit                               HTML     53K 
27: EX-99.10    Miscellaneous Exhibit                               HTML     54K 
28: EX-99.11    Miscellaneous Exhibit                               HTML     54K 
29: EX-99.12    Miscellaneous Exhibit                               HTML     54K 
30: EX-99.13    Miscellaneous Exhibit                               HTML     54K 
26: EX-99.9     Miscellaneous Exhibit                               HTML     54K 
37: R1          Document and Entity Information                     HTML     68K 
38: R2          Condensed Consolidated Balance Sheets               HTML    171K 
39: R3          Condensed Consolidated Balance Sheets               HTML     83K 
                (Parenthetical)                                                  
40: R4          Condensed Consolidated Statements of Operations     HTML    134K 
                and Comprehensive Loss (Unaudited)                               
41: R5          Condensed Consolidated Statements of Operations     HTML     56K 
                and Comprehensive Loss (Unaudited) (Parenthetical)               
42: R6          Condensed Consolidated Statements of Shareholders'  HTML    122K 
                Equity (Unaudited)                                               
43: R7          Condensed Consolidated Statements of Cash Flows     HTML    195K 
                (Unaudited)                                                      
44: R8          Condensed Balance Sheets (Brooklyn                  HTML    144K 
                ImmunoTherapeutics, LLC)                                         
45: R9          Condensed Statements of Operations (Unaudited)      HTML    103K 
                (Brooklyn ImmunoTherapeutics, LLC)                               
46: R10         Condensed Statements of Changes in Members' Equity  HTML    149K 
                (Brooklyn ImmunoTherapeutics, LLC)                               
47: R11         Condensed Statements of Cash Flows (Brooklyn        HTML    265K 
                ImmunoTherapeutics, LLC)                                         
48: R12         Basis of Presentation                               HTML     62K 
49: R13         Organization of Company                             HTML     61K 
50: R14         Merger Agreement and Asset Purchase Agreement       HTML     60K 
51: R15         Covid-19-Update                                     HTML     59K 
52: R16         Going Concern Uncertainty                           HTML     66K 
53: R17         Summary of Significant Accounting Policies And      HTML    131K 
                Estimates                                                        
54: R18         Restricted Cash                                     HTML     59K 
55: R19         Fixed Assets, Net                                   HTML     65K 
56: R20         Fair Value of Financial Instruments                 HTML     62K 
57: R21         Accrued Compensation                                HTML     61K 
58: R22         Concentrations of Risk                              HTML     60K 
59: R23         Revenue Recognition                                 HTML    112K 
60: R24         Basic and Diluted Earnings Per Common Share         HTML     59K 
61: R25         Shareholders' Equity                                HTML    116K 
62: R26         Income Taxes                                        HTML     87K 
63: R27         Debt                                                HTML     66K 
64: R28         Long-term Debt                                      HTML     59K 
65: R29         Leases                                              HTML    110K 
66: R30         Commitments and Contingencies                       HTML     58K 
67: R31         Disposition of Site Equipment to Be Installed and   HTML     61K 
                Fixed Assets                                                     
68: R32         Software Development Costs                          HTML     60K 
69: R33         Goodwill                                            HTML     66K 
70: R34         Accumulated Other Comprehensive Income              HTML     59K 
71: R35         Recent Accounting Pronouncements                    HTML     65K 
72: R36         Retirement Savings Plan                             HTML     57K 
73: R37         Subsequent Events                                   HTML     65K 
74: R38         Organization and Description of Business            HTML     65K 
                Operations (Brooklyn ImmunoTherapeutics, LLC)                    
75: R39         Description of Business (Brooklyn                   HTML     57K 
                ImmunoTherapeutics, LLC) (10-K)                                  
76: R40         Going Concern (Brooklyn ImmunoTherapeutics, LLC)    HTML     72K 
77: R41         Basis of Presentation and Summary of Significant    HTML     72K 
                Accounting Policies (Brooklyn ImmunoTherapeutics,                
                LLC)                                                             
78: R42         Summary of Significant Accounting Policies          HTML    150K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
79: R43         Merger With NTN Buzztime, Inc (Brooklyn             HTML     59K 
                ImmunoTherapeutics, LLC)                                         
80: R44         Fair Value of Financial Instruments (Brooklyn       HTML     74K 
                ImmunoTherapeutics, LLC)                                         
81: R45         Business Combination (Brooklyn ImmunoTherapeutics,  HTML     61K 
                LLC) (10-K)                                                      
82: R46         Property and Equipment (Brooklyn                    HTML     76K 
                ImmunoTherapeutics, LLC)                                         
83: R47         Goodwill and in Process Research and Development    HTML     56K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
84: R48         Security Deposits and Other Assets (Brooklyn        HTML     58K 
                ImmunoTherapeutics, LLC)                                         
85: R49         Accrued Expenses (Brooklyn ImmunoTherapeutics,      HTML     65K 
                LLC)                                                             
86: R50         Investor Deposits (Brooklyn ImmunoTherapeutics,     HTML     55K 
                LLC) (10-K)                                                      
87: R51         Loans Payable (Brooklyn ImmunoTherapeutics, LLC)    HTML     68K 
88: R52         Loans Payable and Loans Payable to Related Parties  HTML     59K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
89: R53         Commitments and Contingencies (Brooklyn             HTML     82K 
                ImmunoTherapeutics, LLC)                                         
90: R54         Stock-Based Compensation (Brooklyn                  HTML     62K 
                ImmunoTherapeutics, LLC)                                         
91: R55         Members' Equity (Brooklyn ImmunoTherapeutics, LLC)  HTML     57K 
92: R56         Stockholders' Deficiency and Members' Equity        HTML     75K 
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
93: R57         Income Tax (Brooklyn ImmunoTherapeutics, LLC)       HTML    101K 
                (10-K)                                                           
94: R58         Subsequent Events (Brooklyn ImmunoTherapeutics,     HTML     72K 
                LLC)                                                             
95: R59         Summary of Significant Accounting Policies And      HTML    180K 
                Estimates (Policies)                                             
96: R60         Basis of Presentation and Summary of Significant    HTML     96K 
                Accounting Policies (Policies) (Brooklyn                         
                ImmunoTherapeutics, LLC)                                         
97: R61         Summary of Significant Accounting Policies          HTML    129K 
                (Policies) (Brooklyn ImmunoTherapeutics, LLC)                    
                (10-K)                                                           
98: R62         Summary of Significant Accounting Policies And      HTML    118K 
                Estimates (Tables)                                               
99: R63         Fixed Assets, Net (Tables)                          HTML     66K 
100: R64         Accrued Compensation (Tables)                       HTML     59K  
101: R65         Revenue Recognition (Tables)                        HTML    118K  
102: R66         Shareholders' Equity (Tables)                       HTML    100K  
103: R67         Income Taxes (Tables)                               HTML     84K  
104: R68         Leases (Tables)                                     HTML     95K  
105: R69         Goodwill (Tables)                                   HTML     63K  
106: R70         Business Combination (Tables) (Brooklyn             HTML     60K  
                ImmunoTherapeutics, LLC) (10-K)                                  
107: R71         Fair Value of Financial Instruments (Tables)        HTML     63K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
108: R72         Property and Equipment (Tables) (Brooklyn           HTML     70K  
                ImmunoTherapeutics, LLC)                                         
109: R73         Accrued Expenses (Tables) (Brooklyn                 HTML     64K  
                ImmunoTherapeutics, LLC)                                         
110: R74         Commitments and Contingencies (Tables) (Brooklyn    HTML     59K  
                ImmunoTherapeutics, LLC) (10-K)                                  
111: R75         Stockholders' Deficiency and Members' Equity        HTML     83K  
                (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)               
112: R76         Income Tax (Tables) (Brooklyn ImmunoTherapeutics,   HTML     89K  
                LLC) (10-K)                                                      
113: R77         Basis of Presentation (Details Narrative)           HTML     55K  
114: R78         Organization of Company (Details Narrative) (10-K)  HTML     61K  
115: R79         Merger Agreement and Asset Purchase Agreement       HTML     74K  
                (Details Narrative)                                              
116: R80         Covid-19-Update (Details Narrative)                 HTML     60K  
117: R81         Going Concern Uncertainty (Details Narrative)       HTML     97K  
118: R82         Going Concern Uncertainty (Details Narrative)       HTML     78K  
                (10-K)                                                           
119: R83         Summary of Significant Accounting Policies and      HTML    199K  
                Estimates (Details Narrative) (10-K)                             
120: R84         Summary of Significant Accounting Policies and      HTML     78K  
                Estimates - Schedule of Disaggregation of Revenues               
                (Details) (10-K)                                                 
121: R85         Summary of Significant Accounting Policies and      HTML     61K  
                Estimates - Schedule of Revenues Geographic                      
                Breakdown (Details) (10-K)                                       
122: R86         Summary of Significant Accounting Policies and      HTML     65K  
                Estimates - Schedule of Contract Liabilities                     
                (Details) (10-K)                                                 
123: R87         Summary of Significant Accounting Policies and      HTML     63K  
                Estimates - Schedule of Unamortized Installation                 
                Cost and Sales Commissions (Details) (10-K)                      
124: R88         Restricted Cash (Details Narrative)                 HTML     72K  
125: R89         Restricted Cash (Details Narrative) (10-K)          HTML     75K  
126: R90         Fixed Assets, Net (Details Narrative) (10-K)        HTML     56K  
127: R91         Fixed Assets, Net - Schedule of Property and        HTML     70K  
                Equipment (Details) (10-K)                                       
128: R92         Fixed Assets, Net - Schedule of Asset Geographic    HTML     59K  
                Breakdown (Details) (10-K)                                       
129: R93         Accrued Compensation - Schedule of Accrued          HTML     66K  
                Compensation (Details) (10-K)                                    
130: R94         Concentrations of Risk (Details Narrative) (10-K)   HTML     75K  
131: R95         Revenue Recognition - (Details Narrative)           HTML     62K  
132: R96         Revenue Recognition - Schedule of Disaggregates     HTML     78K  
                Material Revenue (Details)                                       
133: R97         Revenue Recognition - Schedule of Revenues          HTML     62K  
                Geographic Breakdown (Details)                                   
134: R98         Revenue Recognition - Schedule of Contract          HTML     66K  
                Liabilities (Details)                                            
135: R99         Revenue Recognition - Schedule of Unamortized       HTML     64K  
                Installation Cost and Sales Commissions (Details)                
136: R100        Basic and Diluted Earnings Per Common Share         HTML     57K  
                (Details Narrative)                                              
137: R101        Basic and Diluted Earnings Per Common Share         HTML     57K  
                (Details Narrative) (10-K)                                       
138: R102        Shareholders' Equity (Details Narrative)            HTML    102K  
139: R103        Shareholders' Equity (Details Narrative) (10-K)     HTML    171K  
140: R104        Shareholders' Equity - Schedule of Weighted         HTML     64K  
                Average Assumptions (Details)                                    
141: R105        Shareholders' Equity - Schedule of Weighted         HTML     64K  
                Average Assumptions (Details) (10-K)                             
142: R106        Shareholders' Equity - Schedule of Restricted       HTML     58K  
                Stock and Common Stock Unit Vested (Details)                     
143: R107        Shareholders' Equity - Summary of Stock Option      HTML    104K  
                Activity (Details) (10-K)                                        
144: R108        Shareholders' Equity - Summary of Restricted Stock  HTML     76K  
                Unit Activity (Details) (10-K)                                   
145: R109        Shareholders' Equity - Summary of Warrant           HTML     77K  
                Activities (Details) (10-K)                                      
146: R110        Income Taxes (Details Narrative) (10-K)             HTML     71K  
147: R111        Income Taxes - Schedule of Current and Deferred     HTML     89K  
                Income Tax Provision (Benefit) (Details) (10-K)                  
148: R112        Income Taxes - Schedule of Deferred Tax Assets and  HTML     95K  
                Liabilities (Details) (10-K)                                     
149: R113        Income Taxes - Schedule of Reconciliation of        HTML     72K  
                Expected Income Taxes (Details) (10-K)                           
150: R114        Debt (Details Narrative)                            HTML    159K  
151: R115        Long-term Debt (Details Narrative) (10-K)           HTML     88K  
152: R116        Leases (Details Narrative)                          HTML    122K  
153: R117        Leases (Details Narrative) (10-K)                   HTML     78K  
154: R118        Leases - Schedule of Operating Lease Right-of-use   HTML     79K  
                Assets and Liabilities (Details)                                 
155: R119        Leases - Schedule of Operating Lease Right-of-use   HTML     74K  
                Assets and Liabilities (Details) (10-K)                          
156: R120        Leases - Schedule of Maturities of Operating        HTML     74K  
                Leases (Details) (10-K)                                          
157: R121        Leases - Schedule of Financing Lease Right-of-use   HTML     67K  
                Assets and Liabilities (Details)                                 
158: R122        Leases - Schedule of Financing Lease Right-of-use   HTML     66K  
                Assets and Liabilities (Details) (10-K)                          
159: R123        Leases - Schedule of Maturities of Financing        HTML     64K  
                Leases (Details)                                                 
160: R124        Leases - Schedule of Maturities of Financing        HTML     65K  
                Leases (Details) (10-K)                                          
161: R125        Disposition of Site Equipment to Be Installed and   HTML     70K  
                Fixed Assets (Details Narrative)                                 
162: R126        Software Development Costs (Details Narrative)      HTML     62K  
163: R127        Goodwill (Details Narrative)                        HTML     60K  
164: R128        Goodwill (Details Narrative) (10-K)                 HTML     60K  
165: R129        Goodwill - Schedule of Goodwill (Details)           HTML     63K  
166: R130        Goodwill - Schedule of Goodwill (Details) (10-K)    HTML     64K  
167: R131        Accumulated Other Comprehensive Income (Details     HTML     57K  
                Narrative)                                                       
168: R132        Accumulated Other Comprehensive Income (Details     HTML     57K  
                Narrative) (10-K)                                                
169: R133        Retirement Savings Plan (Details Narrative) (10-K)  HTML     57K  
170: R134        Subsequent Events (Details Narrative)               HTML     63K  
171: R135        Subsequent Events (Details Narrative) (10-K)        HTML    121K  
172: R136        Going Conern (Details Narrative) (Brooklyn          HTML     68K  
                ImmunoTherapeutics, LLC)                                         
173: R137        Basis of Presentation and Summary of Significant    HTML     62K  
                Accounting Policies (Details Narrative) (Brooklyn                
                ImmunoTherapeutics, LLC)                                         
174: R138        Merger With NTN Buzztime, Inc (Details Narrative)   HTML     68K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
175: R139        Fair Value of Financial Instruments (Details        HTML     61K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
176: R140        Fair Value of Financial Instruments - Schedule of   HTML     64K  
                Fair Value of Liabilities (Details) (Brooklyn                    
                ImmunoTherapeutics, LLC)                                         
177: R141        Property and Equipment (Details Narrative)          HTML     56K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
178: R142        Property and Equipment - Schedule of Property and   HTML     68K  
                Equipment (Details) (Brooklyn ImmunoTherapeutics,                
                LLC)                                                             
179: R143        Security Deposits and Other Assets (Details         HTML     62K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
180: R144        Accrued Expenses (Details) (Brooklyn                HTML     67K  
                ImmunoTherapeutics, LLC)                                         
181: R145        Loans Payable (Details Narrative) (Brooklyn         HTML     59K  
                ImmunoTherapeutics, LLC)                                         
182: R146        Commitments and Contingencies (Details Narrative)   HTML     99K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
183: R147        Stock-Based Compensation (Details Narrative)        HTML     56K  
                (Brooklyn ImmunoTherapeutics, LLC)                               
184: R148        Members' Equity (Details Narrative) (Brooklyn       HTML     67K  
                ImmunoTherapeutics, LLC)                                         
185: R149        Going Conern (Details Narrative) (Brooklyn          HTML     86K  
                ImmunoTherapeutics, LLC) (10-K)                                  
186: R150        Summary of Significant Accounting Policies          HTML     72K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
187: R151        Business Combination (Details Narrative) (Brooklyn  HTML     63K  
                ImmunoTherapeutics, LLC) (10-K)                                  
188: R152        Business Combination - Schedule of Purchase Price   HTML     83K  
                for Acquisition (Details) (Brooklyn                              
                ImmunoTherapeutics, LLC) (10-K)                                  
189: R153        Property and Equipment (Details Narative)           HTML     63K  
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
190: R154        Property and Equipment - Schedule of Property and   HTML     68K  
                Equipment (Details) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
191: R155        Goodwill and in Process Research and Development    HTML     59K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
192: R156        Security Deposits and Other Assets (Details         HTML     65K  
                Narrative) (Brooklyn ImmunoTherapeutics, LLC)                    
                (10-K)                                                           
193: R157        Accrued Expenses (Details) (Brooklyn                HTML     70K  
                ImmunoTherapeutics, LLC) (10K)                                   
194: R158        Investor Deposits (Details Narrative) (Brooklyn     HTML     55K  
                ImmunoTherapeutics, LLC) (10-K)                                  
195: R159        Loans Payable and Loans Payable to Related Parties  HTML    101K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
196: R160        Commitments and Contingencies (Details Narrative)   HTML    130K  
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
197: R161        Commitments and Contingencies - Schedule of Future  HTML     72K  
                Commitments of Operating Lease (Details) (Brooklyn               
                ImmunoTherapeutics, LLC)                                         
198: R162        Stockholders' Deficiency and Members' Equity        HTML    167K  
                (Details Narrative) (Brooklyn ImmunoTherapeutics,                
                LLC) (10-K)                                                      
199: R163        Stockholders' Deficiency and Members' Equity -      HTML     92K  
                Schedule of Stock Option Activity (Details)                      
                (Brooklyn ImmunoTherapeutics, LLC) (10-K)                        
200: R164        Stockholders' Deficiency and Members' Equity -      HTML     70K  
                Schedule of Stock Options Outstanding and                        
                Exercisable (Details) (Brooklyn                                  
                ImmunoTherapeutics, LLC) (10-K)                                  
201: R165        Income Tax (Details Narrative) (Brooklyn            HTML     61K  
                ImmunoTherapeutics, LLC) (10-K)                                  
202: R166        Income Tax - Schedule of Income Tax Benefit         HTML     84K  
                (Details) (Brooklyn ImmunoTherapeutics, LLC)                     
                (10-K)                                                           
203: R167        Income Tax - Schedule of Deferred Tax Assets and    HTML     61K  
                Liabilities (Details) (Brooklyn                                  
                ImmunoTherapeutics, LLC) (10-K)                                  
204: R168        Subsequent Events (Details Narrative) (Brooklyn     HTML     61K  
                ImmunoTherapeutics, LLC) (10-K)                                  
206: XML         IDEA XML File -- Filing Summary                      XML    371K  
205: EXCEL       IDEA Workbook of Financial Reports                  XLSX    284K  
31: EX-101.INS  XBRL Instance -- ntn-20200930                        XML   3.47M 
33: EX-101.CAL  XBRL Calculations -- ntn-20200930_cal                XML    459K 
34: EX-101.DEF  XBRL Definitions -- ntn-20200930_def                 XML   2.03M 
35: EX-101.LAB  XBRL Labels -- ntn-20200930_lab                      XML   2.11M 
36: EX-101.PRE  XBRL Presentations -- ntn-20200930_pre               XML   2.34M 
32: EX-101.SCH  XBRL Schema -- ntn-20200930                          XSD    461K 
207: ZIP         XBRL Zipped Folder -- 0001493152-20-022484-xbrl      Zip    337K

‘EX-101.DEF’ — XBRL Definitions — ntn-20200930_def

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://buzztime.com/role/DocumentAndEntityInformation" xlink:href="ntn-20200930.xsd#DocumentAndEntityInformation" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BalanceSheets" xlink:href="ntn-20200930.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BalanceSheetsParenthetical" xlink:href="ntn-20200930.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="ntn-20200930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="ntn-20200930.xsd#StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfShareholdersEquity" xlink:href="ntn-20200930.xsd#StatementsOfShareholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfCashFlows" xlink:href="ntn-20200930.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BalanceSheetsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#BalanceSheetsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfOperationsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#StatementsOfOperationsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfChangesInMembersEquityBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#StatementsOfChangesInMembersEquityBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StatementsOfCashFlowsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#StatementsOfCashFlowsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentation" xlink:href="ntn-20200930.xsd#BasisOfPresentation" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/OrganizationOfCompany" xlink:href="ntn-20200930.xsd#OrganizationOfCompany" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/MergerAgreementAndAssetPurchaseAgreement" xlink:href="ntn-20200930.xsd#MergerAgreementAndAssetPurchaseAgreement" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Covid-19-update" xlink:href="ntn-20200930.xsd#Covid-19-update" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoingConcernUncertainty" xlink:href="ntn-20200930.xsd#GoingConcernUncertainty" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RestrictedCash" xlink:href="ntn-20200930.xsd#RestrictedCash" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNet" xlink:href="ntn-20200930.xsd#FixedAssetsNet" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstruments" xlink:href="ntn-20200930.xsd#FairValueOfFinancialInstruments" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedCompensation" xlink:href="ntn-20200930.xsd#AccruedCompensation" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ConcentrationsOfRisk" xlink:href="ntn-20200930.xsd#ConcentrationsOfRisk" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition" xlink:href="ntn-20200930.xsd#RevenueRecognition" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShare" xlink:href="ntn-20200930.xsd#BasicAndDilutedEarningsPerCommonShare" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity" xlink:href="ntn-20200930.xsd#ShareholdersEquity" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes" xlink:href="ntn-20200930.xsd#IncomeTaxes" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Debt" xlink:href="ntn-20200930.xsd#Debt" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Long-termDebt" xlink:href="ntn-20200930.xsd#Long-termDebt" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases" xlink:href="ntn-20200930.xsd#Leases" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingencies" xlink:href="ntn-20200930.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/DispositionOfSiteEquipmentToBeInstalledAndFixedAssets" xlink:href="ntn-20200930.xsd#DispositionOfSiteEquipmentToBeInstalledAndFixedAssets" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SoftwareDevelopmentCosts" xlink:href="ntn-20200930.xsd#SoftwareDevelopmentCosts" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Goodwill" xlink:href="ntn-20200930.xsd#Goodwill" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="ntn-20200930.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RecentAccountingPronouncements" xlink:href="ntn-20200930.xsd#RecentAccountingPronouncements" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RetirementSavingsPlan" xlink:href="ntn-20200930.xsd#RetirementSavingsPlan" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SubsequentEvents" xlink:href="ntn-20200930.xsd#SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/OrganizationAndDescriptionOfBusinessOperationsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#OrganizationAndDescriptionOfBusinessOperationsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/DescriptionOfBusinessBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#DescriptionOfBusinessBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoingConcernBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#GoingConcernBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/MergerWithNtnBuzztimeIncBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#MergerWithNtnBuzztimeIncBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstrumentsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#FairValueOfFinancialInstrumentsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BusinessCombinationBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#BusinessCombinationBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#PropertyAndEquipmentBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoodwillAndInProcessResearchAndDevelopmentBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#GoodwillAndInProcessResearchAndDevelopmentBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SecurityDepositsAndOtherAssetsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#SecurityDepositsAndOtherAssetsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#AccruedExpensesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/InvestorDepositsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#InvestorDepositsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LoansPayableBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#LoansPayableBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LoansPayableAndLoansPayableToRelatedPartiesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#LoansPayableAndLoansPayableToRelatedPartiesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#CommitmentsAndContingenciesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Stock-basedCompensationBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#Stock-basedCompensationBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/MembersEquityBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#MembersEquityBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#StockholdersDeficiencyAndMembersEquityBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#IncomeTaxBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#SubsequentEventsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesPoliciesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNetTables" xlink:href="ntn-20200930.xsd#FixedAssetsNetTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedCompensationTables" xlink:href="ntn-20200930.xsd#AccruedCompensationTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognitionTables" xlink:href="ntn-20200930.xsd#RevenueRecognitionTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquityTables" xlink:href="ntn-20200930.xsd#ShareholdersEquityTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxesTables" xlink:href="ntn-20200930.xsd#IncomeTaxesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LeasesTables" xlink:href="ntn-20200930.xsd#LeasesTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoodwillTables" xlink:href="ntn-20200930.xsd#GoodwillTables" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BusinessCombinationTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#BusinessCombinationTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstrumentsTablesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#FairValueOfFinancialInstrumentsTablesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentTablesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#PropertyAndEquipmentTablesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesTablesBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#AccruedExpensesTablesBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#CommitmentsAndContingenciesTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#StockholdersDeficiencyAndMembersEquityTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxTablesBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#IncomeTaxTablesBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ntn-20200930.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/OrganizationOfCompanyDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#OrganizationOfCompanyDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/MergerAgreementAndAssetPurchaseAgreementDetailsNarrative" xlink:href="ntn-20200930.xsd#MergerAgreementAndAssetPurchaseAgreementDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Covid-19-updateDetailsNarrative" xlink:href="ntn-20200930.xsd#Covid-19-updateDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoingConcernUncertaintyDetailsNarrative" xlink:href="ntn-20200930.xsd#GoingConcernUncertaintyDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoingConcernUncertaintyDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#GoingConcernUncertaintyDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfDisaggregationOfRevenuesDetails10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfDisaggregationOfRevenuesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfRevenuesGeographicBreakdownDetails10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfRevenuesGeographicBreakdownDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfContractLiabilitiesDetails10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfContractLiabilitiesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesAndEstimates-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RestrictedCashDetailsNarrative" xlink:href="ntn-20200930.xsd#RestrictedCashDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RestrictedCashDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#RestrictedCashDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNetDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#FixedAssetsNetDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNet-ScheduleOfPropertyAndEquipmentDetails10-k" xlink:href="ntn-20200930.xsd#FixedAssetsNet-ScheduleOfPropertyAndEquipmentDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FixedAssetsNet-ScheduleOfAssetGeographicBreakdownDetails10-k" xlink:href="ntn-20200930.xsd#FixedAssetsNet-ScheduleOfAssetGeographicBreakdownDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedCompensation-ScheduleOfAccruedCompensationDetails10-k" xlink:href="ntn-20200930.xsd#AccruedCompensation-ScheduleOfAccruedCompensationDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ConcentrationsOfRiskDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#ConcentrationsOfRiskDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-DetailsNarrative" xlink:href="ntn-20200930.xsd#RevenueRecognition-DetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfDisaggregatesMaterialRevenueDetails" xlink:href="ntn-20200930.xsd#RevenueRecognition-ScheduleOfDisaggregatesMaterialRevenueDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfRevenuesGeographicBreakdownDetails" xlink:href="ntn-20200930.xsd#RevenueRecognition-ScheduleOfRevenuesGeographicBreakdownDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfContractLiabilitiesDetails" xlink:href="ntn-20200930.xsd#RevenueRecognition-ScheduleOfContractLiabilitiesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RevenueRecognition-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails" xlink:href="ntn-20200930.xsd#RevenueRecognition-ScheduleOfUnamortizedInstallationCostAndSalesCommissionsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShareDetailsNarrative" xlink:href="ntn-20200930.xsd#BasicAndDilutedEarningsPerCommonShareDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasicAndDilutedEarningsPerCommonShareDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#BasicAndDilutedEarningsPerCommonShareDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ntn-20200930.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquityDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#ShareholdersEquityDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails" xlink:href="ntn-20200930.xsd#ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails10-k" xlink:href="ntn-20200930.xsd#ShareholdersEquity-ScheduleOfWeightedAverageAssumptionsDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-ScheduleOfRestrictedStockAndCommonStockUnitVestedDetails" xlink:href="ntn-20200930.xsd#ShareholdersEquity-ScheduleOfRestrictedStockAndCommonStockUnitVestedDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-SummaryOfStockOptionActivityDetails10-k" xlink:href="ntn-20200930.xsd#ShareholdersEquity-SummaryOfStockOptionActivityDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-SummaryOfRestrictedStockUnitActivityDetails10-k" xlink:href="ntn-20200930.xsd#ShareholdersEquity-SummaryOfRestrictedStockUnitActivityDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/ShareholdersEquity-SummaryOfWarrantActivitiesDetails10-k" xlink:href="ntn-20200930.xsd#ShareholdersEquity-SummaryOfWarrantActivitiesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxesDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#IncomeTaxesDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes-ScheduleOfCurrentAndDeferredIncomeTaxProvisionBenefitDetails10-k" xlink:href="ntn-20200930.xsd#IncomeTaxes-ScheduleOfCurrentAndDeferredIncomeTaxProvisionBenefitDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:href="ntn-20200930.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxes-ScheduleOfReconciliationOfExpectedIncomeTaxesDetails10-k" xlink:href="ntn-20200930.xsd#IncomeTaxes-ScheduleOfReconciliationOfExpectedIncomeTaxesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/DebtDetailsNarrative" xlink:href="ntn-20200930.xsd#DebtDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Long-termDebtDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#Long-termDebtDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LeasesDetailsNarrative" xlink:href="ntn-20200930.xsd#LeasesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LeasesDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#LeasesDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfOperatingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails10-k" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfMaturitiesOfOperatingLeasesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfFinancingLeaseRight-of-useAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails10-k" xlink:href="ntn-20200930.xsd#Leases-ScheduleOfMaturitiesOfFinancingLeasesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/DispositionOfSiteEquipmentToBeInstalledAndFixedAssetsDetailsNarrative" xlink:href="ntn-20200930.xsd#DispositionOfSiteEquipmentToBeInstalledAndFixedAssetsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SoftwareDevelopmentCostsDetailsNarrative" xlink:href="ntn-20200930.xsd#SoftwareDevelopmentCostsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoodwillDetailsNarrative" xlink:href="ntn-20200930.xsd#GoodwillDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoodwillDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#GoodwillDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Goodwill-ScheduleOfGoodwillDetails" xlink:href="ntn-20200930.xsd#Goodwill-ScheduleOfGoodwillDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Goodwill-ScheduleOfGoodwillDetails10-k" xlink:href="ntn-20200930.xsd#Goodwill-ScheduleOfGoodwillDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccumulatedOtherComprehensiveIncomeDetailsNarrative" xlink:href="ntn-20200930.xsd#AccumulatedOtherComprehensiveIncomeDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccumulatedOtherComprehensiveIncomeDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#AccumulatedOtherComprehensiveIncomeDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/RetirementSavingsPlanDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#RetirementSavingsPlanDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsDetailsNarrative" xlink:href="ntn-20200930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsDetailsNarrative10-k" xlink:href="ntn-20200930.xsd#SubsequentEventsDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/MergerWithNtnBuzztimeIncDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#MergerWithNtnBuzztimeIncDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstrumentsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#FairValueOfFinancialInstrumentsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/FairValueOfFinancialInstruments-ScheduleOfFairValueOfLiabilitiesDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#FairValueOfFinancialInstruments-ScheduleOfFairValueOfLiabilitiesDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#PropertyAndEquipmentDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LoansPayableDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#LoansPayableDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/Stock-basedCompensationDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#Stock-basedCompensationDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/MembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#MembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#GoingConernDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BusinessCombinationDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#BusinessCombinationDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/BusinessCombination-ScheduleOfPurchasePriceForAcquisitionDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#BusinessCombination-ScheduleOfPurchasePriceForAcquisitionDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipmentDetailsNarativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#PropertyAndEquipmentDetailsNarativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/GoodwillAndInProcessResearchAndDevelopmentDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#GoodwillAndInProcessResearchAndDevelopmentDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#SecurityDepositsAndOtherAssetsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc10k" xlink:href="ntn-20200930.xsd#AccruedExpensesDetailsBrooklynImmunotherapeuticsLlc10k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/InvestorDepositsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#InvestorDepositsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/LoansPayableAndLoansPayableToRelatedPartiesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#LoansPayableAndLoansPayableToRelatedPartiesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#CommitmentsAndContingenciesDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/CommitmentsAndContingencies-ScheduleOfFutureCommitmentsOfOperatingLeaseDetailsBrooklynImmunotherapeuticsLlc" xlink:href="ntn-20200930.xsd#CommitmentsAndContingencies-ScheduleOfFutureCommitmentsOfOperatingLeaseDetailsBrooklynImmunotherapeuticsLlc" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#StockholdersDeficiencyAndMembersEquityDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionActivityDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionActivityDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionsOutstandingAndExercisableDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#StockholdersDeficiencyAndMembersEquity-ScheduleOfStockOptionsOutstandingAndExercisableDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTaxDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#IncomeTaxDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTax-ScheduleOfIncomeTaxBenefitDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#IncomeTax-ScheduleOfIncomeTaxBenefitDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/IncomeTax-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#IncomeTax-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetailsBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://buzztime.com/role/SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:href="ntn-20200930.xsd#SubsequentEventsDetailsNarrativeBrooklynImmunotherapeuticsLlc10-k" xlink:type="simple"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll"/>

<link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets"/>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SubscriptionRevenueMember" xlink:label="loc_NTNSubscriptionRevenueMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NTNSubscriptionRevenueMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_HardwareRevenueMember" xlink:label="loc_NTNHardwareRevenueMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NTNHardwareRevenueMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_OtherRevenueMember" xlink:label="loc_NTNOtherRevenueMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_NTNOtherRevenueMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_250"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_250" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_250" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_250"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_DirectOperatingCostsIncludingDepriciationAndAmortization" xlink:label="loc_NTNDirectOperatingCostsIncludingDepriciationAndAmortization_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_250" xlink:to="loc_NTNDirectOperatingCostsIncludingDepriciationAndAmortization_250" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_250" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_250" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments1" xlink:label="loc_us-gaapCapitalizedComputerSoftwareImpairments1_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_250" xlink:to="loc_us-gaapCapitalizedComputerSoftwareImpairments1_250" xlink:type="arc" order="5"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_GoodwillImpairmentLosses" xlink:label="loc_NTNGoodwillImpairmentLosses_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_250" xlink:to="loc_NTNGoodwillImpairmentLosses_250" xlink:type="arc" order="6"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_250" xlink:to="loc_us-gaapDepreciationAndAmortization_250" xlink:type="arc" order="7"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_250" xlink:to="loc_us-gaapOperatingExpenses_250" xlink:type="arc" order="8"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_250"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_250" xlink:type="arc" order="10"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_250" xlink:to="loc_us-gaapInterestExpenseOther_250" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_250" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_250" xlink:type="arc" order="12"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_OtherNonoperatingExpenses" xlink:label="loc_NTNOtherNonoperatingExpenses_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_250" xlink:to="loc_NTNOtherNonoperatingExpenses_250" xlink:type="arc" order="13"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_250" xlink:type="arc" order="14"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_250"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_250"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments_250" xlink:type="arc" order="17"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_250" xlink:type="arc" order="18"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_250"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_250" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract_250"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract_250" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_250" xlink:type="arc" order="23"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_250"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract_250" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_250" xlink:type="arc" order="24"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SeriesACumulativeConvertiblePreferredStockMember" xlink:label="loc_NTNSeriesACumulativeConvertiblePreferredStockMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNSeriesACumulativeConvertiblePreferredStockMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_50"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_50" xlink:type="arc" order="51"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_80" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits" xlink:label="loc_NTNIssuanceOfCommonStockUponVestingOfRestrictedStockUnits_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNIssuanceOfCommonStockUponVestingOfRestrictedStockUnits_80" xlink:type="arc" order="8"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsshares" xlink:label="loc_NTNIssuanceOfCommonStockUponVestingOfRestrictedStockUnitsshares_80"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockDividend_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockDividend_80" xlink:type="arc" order="10"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockDividendsShares" xlink:label="loc_us-gaapStockDividendsShares_80"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsNetOfSharesWithheldForPayrollTaxes" xlink:label="loc_NTNIssuanceOfCommonStockUponVestingOfRestrictedStockUnitsNetOfSharesWithheldForPayrollTaxes_80"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsNetOfSharesWithheldForPayrollTaxesShares" xlink:label="loc_NTNIssuanceOfCommonStockUponVestingOfRestrictedStockUnitsNetOfSharesWithheldForPayrollTaxesShares_80"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_80" xlink:type="arc" order="14"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_80" xlink:type="arc" order="15"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" xlink:type="arc" order="16"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)"/>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/BalanceSheetsBrooklynImmunotherapeuticsLlc" xlink:title="00000008 - Statement - Condensed Balance Sheets (Brooklyn ImmunoTherapeutics, LLC)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_BrooklynImmunotherpeuticsLLCMember" xlink:label="loc_NTNBrooklynImmunotherpeuticsLLCMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_NTNBrooklynImmunotherpeuticsLLCMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_MemberShipUnitsClassAMember" xlink:label="loc_NTNMemberShipUnitsClassAMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NTNMemberShipUnitsClassAMember_30" xlink:type="arc" order="32"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_MemberShipUnitsClassBMember" xlink:label="loc_NTNMemberShipUnitsClassBMember_40"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_MemberShipUnitsClassCMember" xlink:label="loc_NTNMemberShipUnitsClassCMember_50"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapAssetsCurrentAbstract_130" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_130" xlink:to="loc_us-gaapCash_130" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_130"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_InProcessResearchAndDevelopment" xlink:label="loc_NTNInProcessResearchAndDevelopment_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:type="arc" order="12"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:type="arc" order="13"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapAccountsPayableCurrent_130" xlink:type="arc" order="14"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_AccruedExpensesCurrent" xlink:label="loc_NTNAccruedExpensesCurrent_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_NTNAccruedExpensesCurrent_130" xlink:type="arc" order="15"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_InvestorDeposits" xlink:label="loc_NTNInvestorDeposits_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_NTNInvestorDeposits_130" xlink:type="arc" order="16"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLoansPayableCurrent_130" xlink:type="arc" order="17"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_130" xlink:type="arc" order="18"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapLiabilitiesCurrent_130" xlink:type="arc" order="19"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_130" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_PaycheckProtectionProgramLoan" xlink:label="loc_NTNPaycheckProtectionProgramLoan_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_NTNPaycheckProtectionProgramLoan_130" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_130" xlink:to="loc_us-gaapOtherLiabilities_130" xlink:type="arc" order="22"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_130"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_130"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_PreferredStockValueMembershipUnits" xlink:label="loc_NTNPreferredStockValueMembershipUnits_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_NTNPreferredStockValueMembershipUnits_130" xlink:type="arc" order="26"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapCommonStockValue_130" xlink:type="arc" order="27"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_130" xlink:type="arc" order="28"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapStockholdersEquity_130" xlink:type="arc" order="29"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_130"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_130" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_130" xlink:type="arc" order="30"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfOperationsBrooklynImmunotherapeuticsLlc" xlink:title="00000009 - Statement - Condensed Statements of Operations (Unaudited) (Brooklyn ImmunoTherapeutics, LLC)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_BrooklynImmunotherpeuticsLLCMember" xlink:label="loc_NTNBrooklynImmunotherpeuticsLLCMember_0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SuccessorsMember" xlink:label="loc_NTNSuccessorsMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_NTNSuccessorsMember_20" xlink:type="arc" order="22"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_PredecessorsMember" xlink:label="loc_NTNPredecessorsMember_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_NTNPredecessorsMember_40" xlink:type="arc" order="42"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_60" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_60" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_60" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_60" xlink:type="arc" order="2"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_60" xlink:to="loc_us-gaapOperatingExpenses_60" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_60"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_60"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_InterestExpenses" xlink:label="loc_NTNInterestExpenses_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_60" xlink:to="loc_NTNInterestExpenses_60" xlink:type="arc" order="6"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_60" xlink:to="loc_us-gaapNonoperatingIncomeExpense_60" xlink:type="arc" order="7"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_DeemedDividendsOnPreferredStock" xlink:label="loc_NTNDeemedDividendsOnPreferredStock_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNDeemedDividendsOnPreferredStock_60" xlink:type="arc" order="9"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_GainsLossesOnExtinguishmentPreferredStock" xlink:label="loc_NTNGainsLossesOnExtinguishmentPreferredStock_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNGainsLossesOnExtinguishmentPreferredStock_60" xlink:type="arc" order="10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_60" xlink:type="arc" order="11"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfChangesInMembersEquityBrooklynImmunotherapeuticsLlc" xlink:title="00000010 - Statement - Condensed Statements of Changes in Members' Equity (Brooklyn ImmunoTherapeutics, LLC)">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SeriesDPreferredStocksMember" xlink:label="loc_NTNSeriesDPreferredStocksMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNSeriesDPreferredStocksMember_0" xlink:type="arc" order="1"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SeriesCPreferredStocksMember" xlink:label="loc_NTNSeriesCPreferredStocksMember_10"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNSeriesCPreferredStocksMember_10" xlink:type="arc" order="11"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SeriesBPreferredStocksMember" xlink:label="loc_NTNSeriesBPreferredStocksMember_20"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNSeriesBPreferredStocksMember_20" xlink:type="arc" order="21"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SeriesAPreferredStocksMember" xlink:label="loc_NTNSeriesAPreferredStocksMember_30"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNSeriesAPreferredStocksMember_30" xlink:type="arc" order="31"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_50" xlink:type="arc" order="51"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SubscriptionsReceivableRelatedPartiesMember" xlink:label="loc_NTNSubscriptionsReceivableRelatedPartiesMember_60"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNSubscriptionsReceivableRelatedPartiesMember_60" xlink:type="arc" order="61"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_70"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_70" xlink:type="arc" order="71"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_TotalStockHoldersDeficiencyMember" xlink:label="loc_NTNTotalStockHoldersDeficiencyMember_80"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNTotalStockHoldersDeficiencyMember_80" xlink:type="arc" order="81"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_ClassAMembershipUnitsMember" xlink:label="loc_NTNClassAMembershipUnitsMember_90"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNClassAMembershipUnitsMember_90" xlink:type="arc" order="91"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_ClassBMembershipUnitsMember" xlink:label="loc_NTNClassBMembershipUnitsMember_100"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNClassBMembershipUnitsMember_100" xlink:type="arc" order="101"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_ClassCMembershipUnitsMember" xlink:label="loc_NTNClassCMembershipUnitsMember_110"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNClassCMembershipUnitsMember_110" xlink:type="arc" order="111"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_CommonStocksMember" xlink:label="loc_NTNCommonStocksMember_180"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNCommonStocksMember_180" xlink:type="arc" order="181"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_RetainedEarningMember" xlink:label="loc_NTNRetainedEarningMember_190"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NTNRetainedEarningMember_190" xlink:type="arc" order="191"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_BrooklynImmunotherpeuticsLLCMember" xlink:label="loc_NTNBrooklynImmunotherpeuticsLLCMember_0"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_PredecessorsMember" xlink:label="loc_NTNPredecessorsMember_0"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_NTNPredecessorsMember_0" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_SuccessorsMember" xlink:label="loc_NTNSuccessorsMember_90"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_230"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_230"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_IssuanceOfCommonStockUponExchangeOfPreferredStock" xlink:label="loc_NTNIssuanceOfCommonStockUponExchangeOfPreferredStock_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNIssuanceOfCommonStockUponExchangeOfPreferredStock_230" xlink:type="arc" order="3"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_IssuanceOfCommonStockUponExchangeOfPreferredStockShares" xlink:label="loc_NTNIssuanceOfCommonStockUponExchangeOfPreferredStockShares_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNIssuanceOfCommonStockUponExchangeOfPreferredStockShares_230" xlink:type="arc" order="4"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_StockBasedCompensationAmortizationOfRestrictedCommonUnits" xlink:label="loc_NTNStockBasedCompensationAmortizationOfRestrictedCommonUnits_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNStockBasedCompensationAmortizationOfRestrictedCommonUnits_230" xlink:type="arc" order="5"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_StockBasedCompensationIssuanceOfMembershipUnitsForPurchaseOfIrx" xlink:label="loc_NTNStockBasedCompensationIssuanceOfMembershipUnitsForPurchaseOfIrx_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNStockBasedCompensationIssuanceOfMembershipUnitsForPurchaseOfIrx_230" xlink:type="arc" order="6"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_StockBasedCompensationMembershipUnitsIssuedInExchangeForServices" xlink:label="loc_NTNStockBasedCompensationMembershipUnitsIssuedInExchangeForServices_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNStockBasedCompensationMembershipUnitsIssuedInExchangeForServices_230" xlink:type="arc" order="7"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_StockBasedCompensationSaleOfMembersEquity" xlink:label="loc_NTNStockBasedCompensationSaleOfMembersEquity_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNStockBasedCompensationSaleOfMembersEquity_230" xlink:type="arc" order="8"/>

<link:loc xlink:type="locator" xlink:href="ntn-20200930.xsd#NTN_StockBasedCompensationMembersEquityExchangedForLoansPayableAndInterest" xlink:label="loc_NTNStockBasedCompensationMembersEquityExchangedForLoansPayableAndInterest_230"/>

<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NTNStockBasedCompensationMembersEquityExchangedForLoansPayableAndInterest_230" xlink:type="arc" order="9"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_230"/>

</link:definitionLink>

<link:definitionLink xlink:type="extended" xlink:role="http://buzztime.com/role/StatementsOfCashFlowsBrooklynImmunotherapeuticsLlc" xlink:title="00000011 - Statement - Condensed Statements of Cash Flows (Brooklyn ImmunoTherapeutics, LLC)">